Canada Markets closed
  • S&P/TSX

    20,490.36
    -111.74 (-0.54%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.44 (-0.48%)
     
  • CAD/USD

    0.7832
    -0.0054 (-0.6892%)
     
  • CRUDE OIL

    71.96
    -0.65 (-0.90%)
     
  • BTC-CAD

    61,547.60
    -991.36 (-1.59%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • GOLD FUTURES

    1,753.90
    -2.80 (-0.16%)
     
  • RUSSELL 2000

    2,236.87
    +3.96 (+0.18%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • NASDAQ

    15,043.97
    -137.96 (-0.91%)
     
  • VOLATILITY

    20.81
    +2.12 (+11.34%)
     
  • FTSE

    6,963.64
    -63.84 (-0.91%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • CAD/EUR

    0.6677
    -0.0021 (-0.31%)
     

Aptar Reports Second Quarter 2021 Results

  • Oops!
    Something went wrong.
    Please try again later.
·20 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CRYSTAL LAKE, Ill., July 29, 2021--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today reported second quarter results for 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729006201/en/

(Photo: Aptar)

Second Quarter 2021 Summary

  • Reported sales grew 16% driven by strong core sales growth and positive currency effects

  • Core sales (excluding currency effects) increased 10% mainly on double digit core growth in Beauty + Home and Food + Beverage, driven by increased demand for our innovative dispensing solutions along with price adjustments related to rising input costs

  • Reported earnings per share totaled $0.81 (an increase of 29% compared to the prior year)

  • Adjusted earnings per share, excluding restructuring charges, acquisition costs and the loss on an equity investment, totaled $0.91 (an increase of 7% compared to the prior year when neutralizing currency effects)

  • Reported net income totaled $55 million for the second quarter (an increase of 32% compared to the prior year) and $139 million year-to-date (an increase of 43% compared to the prior year)

  • Adjusted EBITDA totaled $148 million for the second quarter (an increase of 8% compared to the prior year) and $300 million year-to-date (an increase of 7% compared to the prior year)

  • Cash flow from operations was $176 million in the first half of 2021 (a decrease of 23% compared to the prior year)

  • Free cash flow was $39 million in the first half of 2021 (a decrease of 63% compared to the prior year) primarily due to increased investments for growth (capital expenditures and working capital)

  • Subsequent to the end of the quarter, the Company announced:

    • A share purchase agreement regarding the acquisition of a majority stake in Voluntis, a pioneer in digital therapeutics

    • A strategic collaboration with YAT, a Chinese online skincare company, to develop a range of products and services for the skincare market

    • An agreement to acquire 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery

Second Quarter Results

For the quarter ended June 30, 2021, reported sales increased 16% to $811 million compared to $699 million in the prior year. Core sales, excluding the impact from changes in currency exchange rates, increased 10%.

Second Quarter Segment Sales Analysis
(Change Over Prior Year)

Pharma

Beauty + Home

Food + Beverage

Total AptarGroup

Core Sales Growth

2%

13%

23%

10%

Acquisitions

0%

0%

0%

0%

Currency Effects (1)

6%

7%

5%

6%

Total Reported Sales Growth

8%

20%

28%

16%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Commenting on the quarter, Stephan B. Tanda, President and CEO, said, "The wide breadth of our innovative solutions and services, serving thousands of customers across multiple markets, continues to be a strength of Aptar. We achieved core sales growth in each segment and consolidated double-digit core sales growth despite the ongoing reduction of allergic rhinitis and cough and cold product inventory levels by customers served by our prescription drug and consumer healthcare units. We will continue to take action to mitigate the effects of a rising input cost environment, which compressed our margins during the quarter, particularly in Beauty + Home and Food + Beverage. Despite the issues we faced in the quarter, we expect a recovery in the second half, especially as we get toward the end of the year."

Aptar’s Beauty + Home segment generated strong core sales growth over the prior year second quarter, which was the height of the pandemic. Approximately 75% of the growth came from increased volumes. Increased sales to the beauty market were driven by demand for fragrance and facial skincare solutions. In the personal care market, increased sales to the hair care and sun care market were offset by declines in personal cleansing, as hand sanitizer demand began to normalize. The home care market experienced another solid quarter with strong demand for Aptar’s valves and pumps for a variety of applications. Price adjustments related to the initial passing through of higher resin and other input costs, and increased tooling sales, also contributed to the top line in the quarter.

Aptar’s Food + Beverage segment reported double-digit core sales growth with price adjustments related to higher resin costs accounting for approximately 60% of the sales increase. Volumes rose on increased demand for specialty food dispensing closures as consumers continued to cook at home, along with modest recovery in the beverage market compared to the prior year.

In the Pharma segment, increased demand for elastomeric components used with injected medicines and active material science solutions more than offset declines in the prescription drug and consumer health care markets. Similar to the first quarter, certain areas of the Pharma segment continue to be impacted by customers drawing down inventory levels as sectors such as allergic rhinitis and cough and cold have been impacted by low levels of patient consumption during the pandemic.

Aptar reported second quarter earnings per share of $0.81 compared to $0.63 during the same period a year ago, an increase of 29%. Second quarter adjusted earnings per share, excluding restructuring charges, acquisitions costs and the loss on an equity investment, were $0.91 and increased 7% from the prior year adjusted earnings per share, including comparable exchange rates, of $0.85.

Year-to-Date Results

For the six months ended June 30, 2021, reported sales increased 12% to $1.59 billion compared to $1.42 billion in the prior year. Core sales, excluding the impacts from changes in currency exchange rates and acquisitions, increased 5%.

Six Months Year-to-Date Segment Sales Analysis
(Change Over Prior Year)

Pharma

Beauty + Home

Food + Beverage

Total AptarGroup

Core Sales Growth

1%

5%

18%

5%

Acquisitions

0%

3%

0%

1%

Currency Effects (1)

6%

5%

4%

6%

Total Reported Sales Growth

7%

13%

22%

12%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Tanda commented on the year-to-date results, "I’m proud of the dedicated efforts of our people and the resiliency and agility we have shown in the first half of the year. We achieved core sales growth in each segment, and consolidated top line core sales growth of 5% with adjusted EBITDA growth of 7%. This is despite headwinds from the unprecedented inflationary environment even though we are implementing pricing adjustments to pass on these effects over time."

For the six months year-to-date, Aptar’s reported earnings per share were $2.05, and increased 39%, compared to $1.47 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisitions costs and the net gain on an equity investment, were $2.01 and increased 10% from prior year adjusted earnings per share, including comparable exchange rates, of $1.83. Free cash flow for the first six months was impacted by higher capital expenditures and changes in working capital, mainly increases in inventory and accounts receivable related to the recent sales growth and order activity.

Outlook

"For the third quarter, the broader macro factors impacting our business are not anticipated to change dramatically from what we experienced in the second quarter. Looking ahead, we believe the second half will initially show gradually improving operating results from our position today, and we expect accelerated improvement toward the end of the year," said Tanda.

Third quarter results are anticipated to reflect continued gradual improvement in Aptar’s beauty and beverage businesses as the reopening of economies is expected to continue at a measured pace given the uncertainties around the COVID-19 variants and limited resumption of intercontinental travel. The current inventory destocking cycle by our customers in the prescription drug market is expected to continue through the third quarter, with improving performance toward the end of the year. Additionally, Aptar expects ongoing steady demand for elastomer components for injection devices in the third quarter. The exceptionally strong custom tooling sales reported in the prior year third quarter by the Pharma segment’s active material science solutions division, is not expected to repeat. While inflation and cost pressures continue to be a headwind, especially in raw material and transportation costs, Aptar will look to implement further price adjustments as necessary to pass on these costs over time.

"As we navigate through what has become a rather bumpy growth trajectory across our different markets, we continue to focus on returns across all areas of our business and anticipate that our consolidated margins will improve as we transition to a more balanced and steady growth pattern," said Tanda. "Our long-term views have not changed. This is a tremendous company with outstanding talent and the fundamental growth story is intact across each of our markets. In addition, we are taking strategic actions such as our recently announced investments in complementary, high-quality businesses that will contribute to that story."

Aptar expects earnings per share for the third quarter of 2021, excluding any restructuring expenses, acquisition costs and changes in the fair value of equity investments, to be in the range of $0.90 to $0.98 and this guidance is based on an effective tax rate range of 28% to 30%.

Cash Dividend

As previously announced, Aptar’s Board of Directors declared a quarterly cash dividend of $0.38 per share. The payment date is August 25, 2021, to stockholders of record as of August 4, 2021.

Open Conference Call

There will be a conference call on Friday, July 30, 2021 at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2021. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the Company's routine activities, such as restructuring and acquisition costs.

This press release contains forward-looking statements, including certain statements set forth under the "Outlook" section of this press release. Words such as "expects," "anticipates," "believes," "estimates," "future," "potential" and other similar expressions or future or conditional verbs such as "will," "should," "would" and "could" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: pandemics, including the impact of the COVID-19 pandemic on our global supply chain and our global customers and operations; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the successful integration of acquisitions and the achievement of the expected benefits of acquisitions and investments; the impact of tax reform legislation including changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; the execution of the business transformation plan; economic conditions worldwide including potential deflationary or inflationary conditions or economic downturn or uncertainty in regions we rely on for growth as a result of the COVID-19 pandemic or otherwise; political conditions worldwide; significant fluctuations in foreign currency exchange rates; changes in customer and/or consumer spending levels; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; the availability of direct labor workers and the increase in direct labor costs; fluctuations in the cost of materials, components and other input costs; the availability of raw materials and components; our ability to successfully implement facility expansions and new facility projects; our ability to increase prices, contain costs and improve productivity; changes in capital availability or cost, including interest rate fluctuations; volatility of global credit markets; cybersecurity threats that could impact our networks and reporting systems; fiscal and monetary policies and other regulations; direct or indirect consequences of acts of war or terrorism; and work stoppages due to labor disputes. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income

Three Months Ended

Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Net Sales

$

811,032

$

699,305

$

1,587,786

$

1,420,858

Cost of Sales (exclusive of depreciation and amortization shown below)

523,050

441,702

1,011,755

892,958

Selling, Research & Development and Administrative

140,913

123,365

275,261

249,557

Depreciation and Amortization

57,790

56,429

115,228

107,235

Restructuring Initiatives

4,876

7,331

8,548

12,170

Operating Income

84,403

70,478

176,994

158,938

Other Income (Expense):

Interest Expense

(7,175

)

(8,734

)

(14,590

)

(17,122

)

Interest Income

624

175

1,005

350

Net Investment (Loss) Gain

(1,611

)

-

15,198

-

Equity in Results of Affiliates

81

(328

)

(434

)

(1,127

)

Miscellaneous, net

(2,028

)

(923

)

(2,991

)

(2,335

)

Income before Income Taxes

74,294

60,668

175,182

138,704

Provision for Income Taxes

19,020

18,808

35,969

41,594

Net Income

$

55,274

$

41,860

$

139,213

$

97,110

Net Loss (Income) Attributable to Noncontrolling Interests

2

(21

)

15

(18

)

Net Income Attributable to AptarGroup, Inc.

$

55,276

$

41,839

$

139,228

$

97,092

Net Income Attributable to AptarGroup, Inc. per Common Share:

Basic

$

0.84

$

0.65

$

2.12

$

1.51

Diluted

$

0.81

$

0.63

$

2.05

$

1.47

Average Numbers of Shares Outstanding:

Basic

65,818

64,262

65,525

64,135

Diluted

68,086

66,384

67,869

66,246

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets

June 30, 2021

December 31, 2020

ASSETS

Cash and Equivalents

$

291,495

$

300,137

Short-term Investments

-

243

Total Cash and Equivalents, and Short-term Investments

291,495

300,380

Accounts and Notes Receivable, Net

635,847

566,623

Inventories

429,440

379,379

Prepaid and Other Current Assets

135,672

122,613

Total Current Assets

1,492,454

1,368,995

Property, Plant and Equipment, Net

1,224,455

1,198,748

Goodwill

887,741

898,521

Other Assets

505,452

523,789

Total Assets

$

4,110,102

$

3,990,053

LIABILITIES AND EQUITY

Short-Term Obligations

$

70,208

$

117,866

Accounts Payable, Accrued and Other Liabilities

712,358

662,463

Total Current Liabilities

782,566

780,329

Long-Term Obligations

1,048,928

1,054,998

Deferred Liabilities and Other

291,945

303,941

Total Liabilities

2,123,439

2,139,268

AptarGroup, Inc. Stockholders' Equity

1,986,282

1,850,389

Noncontrolling Interests in Subsidiaries

381

396

Total Equity

1,986,663

1,850,785

Total Liabilities and Equity

$

4,110,102

$

3,990,053

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Three Months Ended

June 30, 2021

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

811,032

325,343

360,246

125,443

-

-

Reported net income

$

55,274

Reported income taxes

19,020

Reported income before income taxes

74,294

81,806

12,122

9,691

(22,774

)

(6,551

)

Adjustments:

Restructuring initiatives

4,876

38

1,457

117

3,264

Net investment loss

1,611

1,611

Transaction costs related to acquisitions

2,434

2,434

Adjusted earnings before income taxes

83,215

84,278

13,579

9,808

(17,899

)

(6,551

)

Interest expense

7,175

7,175

Interest income

(624

)

(624

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

89,766

84,278

13,579

9,808

(17,899

)

-

Depreciation and amortization

57,790

21,701

24,331

9,818

1,940

-

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

147,556

$

105,979

$

37,910

$

19,626

$

(15,959

)

$

-

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

18.2

%

32.6

%

10.5

%

15.6

%

Three Months Ended

June 30, 2020

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

699,305

301,259

299,786

98,260

-

-

Reported net income

$

41,860

Reported income taxes

18,808

Reported income before income taxes

60,668

85,467

(12,755

)

8,519

(12,004

)

(8,559

)

Adjustments:

Restructuring initiatives

7,331

(111

)

7,324

75

43

Transaction costs related to acquisitions

3,207

3,207

Purchase accounting adjustments related to acquisitions and investments

3,252

293

2,959

Adjusted earnings before income taxes

74,458

85,649

735

8,594

(11,961

)

(8,559

)

Interest expense

8,734

8,734

Interest income

(175

)

(175

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

83,017

85,649

735

8,594

(11,961

)

-

Depreciation and amortization

56,429

18,617

25,939

9,191

2,682

-

Purchase accounting adjustments included in Depreciation and amortization above

(2,867

)

(167

)

(2,700

)

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

136,579

$

104,099

$

23,974

$

17,785

$

(9,279

)

$

-

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

19.5

%

34.6

%

8.0

%

18.1

%

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Six Months Ended

June 30, 2021

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

1,587,786

639,175

707,192

241,419

-

...

-

Reported net income

$

139,213

Reported income taxes

35,969

Reported income before income taxes

175,182

169,476

21,810

19,701

(22,220

)

(13,585

)

Adjustments:

Restructuring initiatives

8,548

73

2,553

38

5,884

Net investment gain

(15,198

)

(15,198

)

Transaction costs related to acquisitions

2,434

2,434

Adjusted earnings before income taxes

170,966

171,983

24,363

19,739

(31,534

)

(13,585

)

Interest expense

14,590

14,590

Interest income

(1,005

)

(1,005

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

184,551

171,983

24,363

19,739

(31,534

)

-

Depreciation and amortization

115,228

42,480

48,903

19,877

3,968

-

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

299,779

$

214,463

$

73,266

$

39,616

$

(27,566

)

$

-

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

18.9

%

33.6

%

10.4

%

16.4

%

Six Months Ended

June 30, 2020

Consolidated

Pharma

Beauty + Home

Food + Beverage

Corporate & Other

Net Interest

Net Sales

$

1,420,858

598,455

624,346

198,057

-

-

Reported net income

$

97,110

Reported income taxes

41,594

Reported income before income taxes

138,704

175,321

(5,647

)

14,481

(28,679

)

(16,772

)

Adjustments:

Restructuring initiatives

12,170

(142

)

12,231

178

(97

)

Transaction costs related to acquisitions

4,591

4,591

Purchase accounting adjustments related to acquisitions and investments

4,642

1,421

3,221

Adjusted earnings before income taxes

160,107

176,600

14,396

14,659

(28,776

)

(16,772

)

Interest expense

17,122

17,122

Interest income

(350

)

(350

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

176,879

176,600

14,396

14,659

(28,776

)

-

Depreciation and amortization

107,235

36,508

46,525

18,533

5,669

-

Purchase accounting adjustments included in Depreciation and amortization above

(3,367

)

(667

)

(2,700

)

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

280,747

$

212,441

$

58,221

$

33,192

$

(23,107

)

$

-

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

19.8

%

35.5

%

9.3

%

16.8

%

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Income before Income Taxes

$

74,294

$

60,668

$

175,182

$

138,704

Adjustments:

Restructuring initiatives

4,876

7,331

8,548

12,170

Net investment loss (gain)

1,611

-

(15,198

)

-

Transaction costs related to acquisitions

2,434

3,207

2,434

4,591

Purchase accounting adjustments related to acquisitions and investments

-

3,252

-

4,642

Foreign currency effects (1)

4,640

10,296

Adjusted Earnings before Income Taxes

$

83,215

$

79,098

$

170,966

$

170,403

Provision for Income Taxes

$

19,020

$

18,808

$

35,969

$

41,594

Adjustments:

Restructuring initiatives

1,144

1,503

1,985

2,702

Net investment loss (gain)

370

-

(3,496

)

-

Transaction costs related to acquisitions

442

481

442

689

Purchase accounting adjustments related to acquisitions and investments

-

727

-

1,026

Foreign currency effects (1)

1,440

3,089

Adjusted Provision for Income Taxes

$

20,976

$

22,959

$

34,900

$

49,100

Net Income Attributable to Noncontrolling Interests

$

2

$

(21

)

$

15

$

(18

)

Net Income Attributable to AptarGroup, Inc.

$

55,276

$

41,839

$

139,228

$

97,092

Adjustments:

Restructuring initiatives

3,732

5,828

6,563

9,468

Net investment loss (gain)

1,241

-

(11,702

)

-

Transaction costs related to acquisitions

1,992

2,726

1,992

3,902

Purchase accounting adjustments related to acquisitions and investments

-

2,525

-

3,616

Foreign currency effects (1)

3,200

7,207

Adjusted Net Income Attributable to AptarGroup, Inc.

$

62,241

$

56,118

$

136,081

$

121,285

Average Number of Diluted Shares Outstanding

68,086

66,384

67,869

66,246

Net Income Attributable to AptarGroup, Inc. Per Diluted Share

$

0.81

$

0.63

$

2.05

$

1.47

Adjustments:

Restructuring initiatives

0.05

0.09

0.10

0.14

Net investment loss (gain)

0.02

-

(0.17

)

-

Transaction costs related to acquisitions

0.03

0.04

0.03

0.06

Purchase accounting adjustments related to acquisitions and investments

-

0.04

-

0.05

Foreign currency effects (1)

0.05

0.11

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share

$

0.91

$

0.85

$

2.01

$

1.83

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

AptarGroup, Inc.

Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

(In Thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Net Cash Provided by Operations

$

103,396

$

142,653

$

175,581

$

227,686

Less:

Capital Expenditures

$

73,155

$

61,361

$

137,039

$

122,986

Free Cash Flow

$

30,241

$

81,292

$

38,542

$

104,700

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ending

September 30,

Expected 2021

2020

Income before Income Taxes

$

89,139

Adjustments:

Restructuring initiatives

3,415

Net investment loss (gain)

-

Transaction costs related to acquisitions

221

Purchase accounting adjustments related to acquisitions and investments

-

Foreign currency effects (1)

1,105

Adjusted Earnings before Income Taxes

$

93,880

Provision for Income Taxes

$

25,404

Adjustments:

Restructuring initiatives

598

Net investment loss (gain)

-

Transaction costs related to acquisitions

25

Purchase accounting adjustments related to acquisitions and investments

-

Foreign currency effects (1)

315

Adjusted Provision for Income Taxes

$

26,342

Net Income Attributable to Noncontrolling Interests

$

(19

)

Net Income Attributable to AptarGroup, Inc.

$

63,716

Adjustments:

Restructuring initiatives

2,817

Net investment loss (gain)

-

Transaction costs related to acquisitions

196

Purchase accounting adjustments related to acquisitions and investments

-

Foreign currency effects (1)

790

Adjusted Net Income Attributable to AptarGroup, Inc.

$

67,519

Average Number of Diluted Shares Outstanding

66,922

Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)

$

0.95

Adjustments:

Restructuring initiatives

0.05

Net investment loss (gain)

-

Transaction costs related to acquisitions

-

Purchase accounting adjustments related to acquisitions and investments

-

Foreign currency effects (1)

0.01

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)

$0.90 - $0.98

$

1.01

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings per share using foreign currency exchange rates.

(2) AptarGroup’s expected earnings per share range for the third quarter of 2021, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 28% to 30%. This tax rate range compares to our third quarter of 2020 effective tax rate of 28% on reported and adjusted earnings per share.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729006201/en/

Contacts

Investor Relations Contact:

Matt DellaMaria
matt.dellamaria@aptar.com
815-479-5530

Media Contact:

Katie Reardon
katie.reardon@aptar.com
815-479-5671

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting